Kamada (KMDA)

[midastouch017]

Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S.

https://www.globenewswire.com/news-release/2021/03/03/2186052/0/en/Kamada-Announces-the-Closing-of-the-Acquisition-of-the-FDA-Licensed-Plasma-Collection-Center-from-Blood-and-Plasma-Research-Inc-in-the-U-S.html

Transaction Furthers Kamada’s Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company

Kamada is Already Actively Engaged in the Expansion of the Center’s Collection Capacity; Planning to Open Additional Plasma Collection Centers

REHOVOT, Israel, March 03, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today updated that it has completed the previously announced acquisition of the FDA licensed plasma collection center and certain related rights and assets from the privately-held Blood and Plasma Research, Inc (B&PR) of Beaumont, TX, USA.

“This acquisition furthers our strategic goal of becoming a fully integrated specialty plasma company,” said Amir London, CEO of Kamada. “We are already actively engaged in the expansion of the hyperimmune plasma collection capacity of the center and we plan on leveraging its FDA license to open additional centers in the U.S. We are committed to growing our hyperimmune IgG portfolio and believe this acquisition is a significant strategic step in this direction.”

The acquisition for a total consideration of approximately $1.66 million, was consummated through Kamada Plasma LLC, a newly formed wholly owned subsidiary of Kamada, which will operate the Company’s plasma collection activity in the U.S.

Kamada retained Jackson Walker LLP as legal advisors for this acquisition.